慢性移植物抗宿主病的白介素-17抑制:人体概念验证
银屑病样慢性移植物抗宿主病(GvHD)是异基因造血干细胞移植后罕见的临床表现,对激素持久应答差,动物模型和人体数据提示供者T细胞产生白介素-17可能诱导该病。本文首次描述一例银屑病样GvHD患者在接受抗白介素-17A抗体司库奇尤单抗(secukinumab)治疗后获得持续改善。
要点
- 银屑病样慢性GvHD对激素持久应答差,需考虑替代治疗。
- 供者T细胞产生白介素-17可能参与银屑病样GvHD发病。
- 司库奇尤单抗(抗IL-17A)在该例患者中实现持续改善。
核心结论
- 抗白介素-17A抗体司库奇尤单抗(secukinumab)在一例银屑病样慢性GvHD患者中实现持续改善,为首个白介素-17阻断治疗该病的人体概念验证。
研究设计与样本
- 本文为病例报告,描述一例银屑病样慢性GvHD患者接受司库奇尤单抗治疗并持续改善。
主要发现
- 银屑病样慢性GvHD的特征是T辅助17 CD8+ T细胞浸润并产生干扰素-γ和白介素-17。
- 该例患者在接受司库奇尤单抗治疗后获得持续改善。
关键数值与推荐
- 银屑病样慢性GvHD对激素的持久应答差。
- 尚无白介素-17阻断治疗银屑病样慢性GvHD患者疗效的数据。
临床怎么用
- 对于激素应答不佳的银屑病样慢性GvHD,可考虑白介素-17A阻断作为潜在治疗选择。
局限性
- 本文仅为单例病例报告,证据级别有限,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psoriasiform chronic graft-versus-host disease (GvHD) is a rare clinical presentation recently described after allogeneic haematopoietic stem cell transplantation. It is characterized by the combination of clinical and pathological characteristics of psoriasis together with pathological features of chronic GvHD. As described for psoriasis, psoriasiform chronic GvHD is characterized by the infiltration of T helper 17 CD8+ T cells producing both interferon-γ and interleukin-17. However, no data are available about the efficacy of interleukin-17 blockade in the treatment of patients with psoriasiform chronic GvHD. What's already known about this topic? Psoriasiform chronic graft-versus-host disease (GvHD) is a rare clinical presentation with a poor durable response to steroids. Animal models and human data suggest that psoriasiform GvHD could be induced through interleukin-17 production by donor T cells. What does this study add? We describe the first case of a patient with psoriasiform GvHD and persistent improvement on treatment with secukinumab, an anti-interleukin-17A antibody.
引用
- Debureaux PE, de Masson A, Battistella M, et al. Chronic graft-versus-host disease and inhibition of interleukin-17: proof of concept in humans. Br J Dermatol. 2019. PMID: 31175666. doi:10.1111/bjd.18214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。